Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «docetaxel»

docetaxel


docetaxel

Generic Name: docetaxel (doe se TAX el)Brand Names: Taxotere

What is docetaxel?

Docetaxel is a cancer medicine that slows the growth and spread of cancer cells in the body.

Docetaxel is used to treat breast cancer, lung cancer, prostate cancer, stomach cancer, and head/neck cancer.

Docetaxel may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about docetaxel?

Do not use this medication without your doctor's consent if you are pregnant. It could cause harm to the unborn baby. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment. Before being treated with docetaxel, tell your doctor if you have ever been treated with cisplatin (Platinol), or if you have liver disease, congestive heart failure, fluid retention, swelling problems, or if you have ever had an allergic reaction to docetaxel.

Docetaxel can be harmful if it gets on your skin during an IV infusion. If this happens, wash the skin thoroughly with soap and warm water.

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.

Docetaxel can lower the blood cells that help your body fight infections. This can make it easier for you to get sick from being around others who are ill. To be sure your blood cells do not get too low, your blood will need to be tested on a regular basis. Your liver function may also need to be tested. It is important that you not miss any scheduled visits to your doctor.

Avoid contact with people who have colds, the flu, or other contagious illnesses. Contact your doctor immediately if you develop signs of infection, especially fever.

There are many other drugs that can interact with docetaxel. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

What should I discuss with my healthcare provider before using docetaxel?

Before being treated with docetaxel, tell your doctor if you have ever been treated with cisplatin (Platinol), or if you have:
  • liver disease;
  • congestive heart failure;

  • fluid retention or swelling problems; or

  • if you have ever had an allergic reaction to docetaxel.

If you have any of these conditions, you may need a dose adjustment or special tests to safely receive docetaxel.

FDA pregnancy category D. This medication can cause harm to an unborn baby. Do not use docetaxel without telling your doctor if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment. It is not known whether docetaxel passes into breast milk or if it could harm a nursing baby. Do not receive docetaxel without telling your doctor if you are breast-feeding a baby.

Adults older than 65 may be more sensitive to the side effects of docetaxel.

How is docetaxel used?

Docetaxel is given as an injection through a needle placed into a vein. You will receive this medicine in a clinic or hospital setting. Docetaxel must be given slowly through an IV and it may take up to an hour to complete your dose.

Your doctor may prescribe a steroid medicine for you to take for a few days before your injection. This will help prevent swelling or an allergic reaction to docetaxel. Do not miss any doses of the steroid.

Docetaxel must be given slowly through an IV and it may take up to an hour to complete your dose.

Docetaxel can be harmful if it gets on your skin during an IV infusion. If this happens, wash the skin thoroughly with soap and warm water.

Docetaxel is usually given once every 3 weeks, and you may receive other cancer medicines at the same time. Your doctor will determine a treatment schedule for you based on the type of cancer being treated and other factors.

Docetaxel can lower the blood cells that help your body fight infections. This can make it easier for you to get sick from being around others who are ill. To be sure your blood cells do not get too low, your blood will need to be tested on a regular basis. Your liver function may also need to be tested. Do not miss any scheduled appointments.

What happens if I miss a dose?

Call your doctor for instructions if you miss a dose of docetaxel or the steroid medicine.

What happens if I overdose?

Seek emergency medical attention if you think you have received too much of this medicine.

Overdose symptoms may include fever, chills, body aches, flu symptoms, numbness, burning, pain, or tingly feeling, or white patches or sores inside your mouth or on your lips.

What should I avoid while using docetaxel?

Avoid getting a flu shot or vaccine while you are being treated with docetaxel. Vaccines may not work as well or could make you sick while you are using docetaxel.

Avoid contact with people who have colds, the flu, or other contagious illnesses. Contact your doctor immediately if you develop signs of infection, especially fever.

Avoid allowing this medicine to get on your skin during an IV infusion. If this does happen, wash the skin thoroughly with soap and warm water.

Docetaxel side effects

Some people receiving a docetaxel injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, light-headed, warm, or itchy, or if you have chest tightness or trouble breathing during the injection.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
  • easy bruising or bleeding, unusual weakness;

  • feeling like you might pass out;

  • fever, chills, body aches, flu symptoms;

  • severe diarrhea;

  • skin changes or bruising where the IV was placed;

  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);

  • feeling short of breath, even with mild exertion;

  • swelling of your ankles or feet, weight gain;

  • a red, blistering, peeling skin rash; or

  • numbness, burning, pain, or tingly feeling.

Less serious side effects may include:

  • feeling weak or tired;

  • white patches or sores inside your mouth or on your lips;

  • mild nausea, vomiting, diarrhea, constipation, or loss of appetite;

  • watery eyes;

  • changes in menstrual periods;

  • temporary hair loss; or

  • fingernail or toenail changes.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Docetaxel Dosing Information

Usual Adult Dose for Non-Small Cell Lung Cancer:

Initial dose: 75 mg/m2 IV over one hour. Courses of docetaxel may be repeated at 3 week intervals, after adequate recovery from toxicity.When docetaxel is used as monotherapy for NSCLC treatment after failure of prior platinum based chemotherapy, the following guidelines apply: For patients who are dosed initially at 75 mg/m2 and who experience either febrile neutropenia, neutrophils less than 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions, or other grade 3 or 4 nonhematologic toxicities during docetaxel treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg/m2. Patients who develop a grade 3 or greater peripheral neuropathy should have docetaxel treatment discontinued entirely.When docetaxel is used as a part of combination chemotherapy in chemotherapy-naive NSCLC patients, the following guidelines apply: For patients who are dosed initially at 75 mg/m2 in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is less than 25,000 cells/mm3, in patients who experience febrile neutropenia, and in patients with serious nonhematologic toxicities, the docetaxel dosage in subsequent cycles should be reduced to 65 mg/m2. In patients who require a further dose reduction, a dose of 50 mg/m2 of docetaxel is recommended.

Usual Adult Dose for Breast Cancer:

Locally advanced or metastatic breast cancer after failure of prior treatment:60 to 100 mg/m?? IV over one hour. Courses of docetaxel may be repeated at 3 week intervals, after adequate recovery from toxicity.Patients who are initially dosed at 100 mg/m2 and who experience either febrile neutropenia, neutrophils less than 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions, or severe peripheral neuropathy during therapy should have their dosage decreased to 75 mg/m2. If the patient continues to experience these reactions, the dosage should either be further decreased 55 mg/m2 or treatment should be discontinued. Conversely, patients who are dosed initially at 60 mg/m2 and who do not experience the above effects, may tolerate higher doses. Patients who develop a grade 3 or greater peripheral neuropathy should have docetaxel treatment discontinued entirely.Docetaxel in combination with doxorubicin and cyclophosphamide recommended as adjuvant treatment of patients with operable node-positive breast cancer:docetaxel 75 mg/m2 intravenously administered one hour after doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 3 weeks for 6 courses. Prophylactic G-CSF may be used to mitigate the risk of hematologic toxicities.Docetaxel in combination with doxorubicin and cyclophosphamide should be administered when the neutrophil count is > or = 1,500 cells/mm3. Patients who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their docetaxel reduced to 60 mg/m2. Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel therapy should have their dosage of docetaxel reduced from 75 mg/m2 to 60 mg/m2. If the patient continues to experience these reactions at 60 mg/m2, treatment should be discontinued.Patients should be premedicated with oral corticosteroids such as dexamethasone 16 mg per day (e.g. 8 mg twice a day) for 3 days starting one day prior to docetaxel administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions.

Usual Adult Dose for Prostate Cancer:

Initial dose: Docetaxel 75 mg/m2 intravenously once over one hour. Prednisone 5 mg orally twice daily is administered continuously. For hormone-refractory metastatic prostate cancer, given the concurrent use of prednisone, the recommended premedication regimen is oral dexamethasone 8 mg, at 12 hours, 3 hours, and 1 hour before the docetaxel infusion. Courses of docetaxel may be repeated at 3 week intervals, after adequate recovery from toxicity.Docetaxel should be administered when the neutrophil count is greater than or equal to 1,500 cells/mm3. Patients who experience either febrile neutropenia, neutrophils less than 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel therapy should have the dosage of docetaxel reduced from 75 mg/m2 to 60 mg/m2. If the patient continues to experience these reactions at 60 mg/m2, the treatment should be discontinued.

Usual Adult Dose for Gastric Cancer:

Initial dose: Docetaxel 75 mg/m2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m2 as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m2 per day given as a 24 hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration. Patients should be premedicated with oral corticosteroids such as dexamethasone 16 mg per day (e.g. 8 mg twice a day) for 3 days starting one day prior to docetaxel administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions.Patients treated with docetaxel in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. In the study, G-CSF was recommended during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than 7 days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 mg/m2 to 60 mg/m2. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced from 60 mg/m2 to 45 mg/m2. In case of Grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m2 to 60 mg/m2. Patients should not be treated with subsequent cycles of docetaxel until neutrophils recover to a level greater than 1,500 cells/mm3 and platelets recover to a level greater than 100,000 cells/mm3. Treatment should be discontinued if these toxicities persist.The recommended dose modifications for gastrointestinal toxicities in patients treated with docetaxel in combination with cisplatin and fluorouracil are as follows:Diarrhea grade 3: For the first episode, reduce the dose of fluorouracil by 20%.For the second episode, also reduce the docetaxel dose by 20%.Diarrhea grade 4: For the first episode, reduce the dose of both docetaxel and fluorouracil by 20%.For the second episode, discontinue treatment.Stomatitis grade 3: For the first episode, reduce the dose of fluorouracil by 20%.For the second episode, stop fluorouracil only, at all subsequent cycles.For the third episode, reduce the dose of docetaxel by 20%.Stomatitis grade 4: For the first episode, stop fluorouracil only, at all subsequent cycles.For the second episode, reduce the dose of docetaxel by 20%.

Usual Adult Dose for Head and Neck Cancer:

In combination with cisplatin and fluorouracil for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck:Initial dose: 75 mg/m2 as a 1 hour intravenous infusionThis is followed by cisplatin 75 mg/m2 intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.Patients must receive premedication with antiemetics and appropriate hydration (prior to and after cisplatin administration). All patients on the docetaxel-containing arm of the TAX 323 study also received prophylactic antibiotics.Patients treated with docetaxel in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. In the study, G-CSF was recommended during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than 7 days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 mg/m2 to 60 mg/m2. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced from 60 mg/m2 to 45 mg/m2. In case of Grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m2 to 60 mg/m2. Patients should not be treated with subsequent cycles of docetaxel until neutrophils recover to a level greater than 1,500 cells/mm3 and platelets recover to a level greater than 100,000 cells/mm3. Treatment should be discontinued if these toxicities persist.The recommended dose modifications for gastrointestinal toxicities in patients treated with docetaxel in combination with cisplatin and fluorouracil are as follows:Diarrhea grade 3: For the first episode, reduce the dose of fluorouracil by 20%.For the second episode, also reduce the docetaxel dose by 20%.Diarrhea grade 4: For the first episode, reduce the dose of both docetaxel and fluorouracil by 20%.For the second episode, discontinue treatment.Stomatitis grade 3: For the first episode, reduce the dose of fluorouracil by 20%.For the second episode, stop fluorouracil only, at all subsequent cycles.For the third episode, reduce the dose of docetaxel by 20%.Stomatitis grade 4: For the first episode, stop fluorouracil only, at all subsequent cycles.For the second episode, reduce the dose of docetaxel by 20%.

What other drugs will affect docetaxel?

Do not receive "live" vaccines during treatment with docetaxel. Administration of a live vaccine may be dangerous during treatment with docetaxel.

There are many other drugs that can interact with docetaxel. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

  • Your doctor or pharmacist can provide more information about docetaxel.
  • Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
  • Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2006 Cerner Multum, Inc. Version: 2.04. Revision Date: 4/12/2009 4:42:18 PM.
  • docetaxel Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
  • Docetaxel Professional Patient Advice (Wolters Kluwer)
  • Docetaxel MedFacts Consumer Leaflet (Wolters Kluwer)
  • Taxotere Prescribing Information (FDA)
  • Taxotere Consumer Overview

See Also...

Comment «docetaxel»